Retirement Planning Co of New England Inc. Has $4.29 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Retirement Planning Co of New England Inc. boosted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 3.1% during the fourth quarter, Holdings Channel reports. The firm owned 514,832 shares of the company’s stock after purchasing an additional 15,327 shares during the quarter. Zevra Therapeutics comprises about 2.1% of Retirement Planning Co of New England Inc.’s holdings, making the stock its 6th biggest position. Retirement Planning Co of New England Inc.’s holdings in Zevra Therapeutics were worth $4,294,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Zevra Therapeutics in the third quarter worth about $94,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Zevra Therapeutics in the 4th quarter worth approximately $94,000. Intech Investment Management LLC purchased a new position in shares of Zevra Therapeutics in the third quarter worth approximately $95,000. Virtu Financial LLC purchased a new position in shares of Zevra Therapeutics in the third quarter worth approximately $127,000. Finally, Rubric Capital Management LP bought a new stake in Zevra Therapeutics during the third quarter valued at approximately $139,000. Institutional investors own 35.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ZVRA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim lifted their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group lifted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and a consensus price target of $22.14.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $8.35 on Tuesday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76. The stock’s 50-day simple moving average is $7.92 and its 200-day simple moving average is $8.17. The company has a market capitalization of $451.87 million, a price-to-earnings ratio of -4.24 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million. As a group, analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is owned by insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.